Cellply raises 7.15 million euros

The Italian DeepTech Cellply has closed a financing round of 7.15 million euros to date. The round marks the biotech's largest capital raise to date and is intended to accelerate its international expansion and the further development of technologies for cell and gene therapies. The financing was led by ENEA Tech e Biomedical. Existing investors also participated, including CDP Venture Capital via the "Fondo Rilancio" fund.

Cellply develops analysis and quality assurance solutions for advanced therapy medicinal products (ATMPs), i.e. novel cell, gene and regenerative therapies. The focus here is on the functional analysis of individual cells in order to be able to evaluate the efficacy and quality of modern therapies more precisely.

International scaling of the VivaCyte platform

Cellply intends to use the fresh capital to roll out its VivaCyte platform internationally and expand its commercial presence in key markets. At the same time, the company is working on new automated test procedures for the quality control of cell therapies.

The solutions are intended to help manufacturers measure cell potency more precisely and make approval processes for therapies more efficient. Standardized quality controls are a decisive factor for scalability and market access, especially in the field of personalized medicine and regenerative therapies.

AI and single cell analytics

Cellply combines patented microfluidic technology with AI-supported image analysis and automation. This allows immune cells to be analysed and functionally characterized at the single-cell level. The aim is to make the development of new immune and cell therapies faster, more precise and more cost-efficient. In the long term, the company aims to establish itself as a leading provider of analytical tools for research and quality control in the field of cell therapies.

Reinforcement on the board

Alongside the financing round, Cellply is also expanding its management team. New to the Board of Directors is Miro Venturi, who has many years of experience in the fields of diagnostics, life sciences and precision medicine. He will support the company in its international growth and the scaling of the platform.

Cellply was founded in Bologna and is positioned at the interface of biotechnology, AI and medical technology. The company develops solutions to make the development and industrial production of modern cell therapies more efficient and reliable.